How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium

被引:27
作者
Neesgaard, Bastian [1 ]
Mocroft, Amanda [2 ]
Greenberg, Lauren [2 ]
Larsen, Jakob Friis [1 ]
Wandeler, Gilles [3 ]
Zangerle, Robert [4 ]
Gunthard, Huldrych [5 ,6 ]
Smith, Colette [7 ]
De Wit, Stephane [8 ]
Mussini, Cristina [9 ]
Castagna, Antonella [10 ]
Monforte, Antonella D'Arminio [11 ]
Vehreschild, Joerg Janne [12 ]
Wasmuth, Jan-Christian [13 ,14 ]
Pradier, Christian [15 ,16 ]
Chkhartishvili, Nikoloz [17 ]
Wit, Ferdinand W. N. M. [18 ]
Law, Matthew [19 ]
Sonnerborg, Anders [20 ]
Bruguera, Andreau [21 ]
Stephan, Christoph [22 ]
Vannappagari, Vani [23 ]
Haubrich, Richard [24 ]
Kirk, Ole [1 ]
Podlekareva, Daria [1 ]
Kowalska, Justyna [25 ]
Raben, Dorthe [1 ]
Rockstroh, Juergen [13 ,14 ]
Peters, Lars [1 ]
Parades, Roger [26 ]
Grabmeier-Pfistershammer, Katharina [27 ]
Scherrer, Alexandra [5 ,6 ]
Johnson, Margaret [7 ]
Necsoi, Coca [8 ]
Borghi, Vanni [9 ]
Muccini, Camilla [10 ]
Tserstvadze, Tengiz [17 ]
Petoumenos, Kathy [19 ]
Volny-Anne, Alain [28 ]
Lundgren, Jens [1 ]
Ryom, Lene [1 ]
机构
[1] Univ Copenhagen, Dept Infect Dis, CHIP, Rigshospitalet, Copenhagen, Denmark
[2] UCL, Inst Global Hlth, Ctr Clin Res Epidemiol Modelling & Evaluat CREME, London, England
[3] Univ Bern, Bern Univ Hosp, Dept Infect Dis, Bern, Switzerland
[4] Med Univ Innsbruck, Austrian HIV Cohort Study AHIVCOS, Innsbruch, Austria
[5] Univ Hosp Zurich, Div Infect Dis, Zurich, Switzerland
[6] Univ Hosp Zurich, Hosp Epidemiol, Zurich, Switzerland
[7] Royal Free HIV Cohort, London, England
[8] St Pierre Univ Hosp Bruxelles, Dept Infect Dis, Brussels, Belgium
[9] Univ Modena, Modena HIV Cohort, Modena, Italy
[10] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Milan, Italy
[11] ASST Santi Paolo & Carlo, Italian Cohort Naive Antiretrovirals ICONA, Milan, Italy
[12] Univ Hosp Cologne, Cologne, Germany
[13] Univ Klinikum Bonn, Bonn, Germany
[14] Med Fak, Bonn, Germany
[15] Univ Cote dAzur, Nice HIV Cohort, Nice, France
[16] CHU Nice, Nice, France
[17] Infect Dis AIDS & Clin Immunol Res Ctr, Georgian Natl AIDS Hlth Informat Syst AIDS HIS, Tbilisi, Georgia
[18] Stichting HIV Monitoring, AIDS Therapy Evaluat Netherlands ATHENA Cohort, Amsterdam, Netherlands
[19] UNSW Sidney, Australian HIV Observat Database AHOD, Sydney, NSW, Australia
[20] Karolinska Univ Hosp, Swedish InfCare HIV Cohort, Stockholm, Sweden
[21] Ctr Estudis Epidemiol ITS & VIH Catalunya CEEISCA, PISCIS Cohort Study, Badalona, Spain
[22] Johann Wolfgang Goethe Univ Hosp, Frankfurt HIV Cohort Study, Frankfurt, Germany
[23] ViiV Healthcare, Res Triangle Pk, NC USA
[24] Gilead Sci, Foster City, CA USA
[25] Med Univ Warsaw, Warsaw, Poland
[26] Hosp Badalona Germans Trias & Pujol, Badalona, Spain
[27] Med Univ Wien, Austrian HIV Cohort Study AHIVCOS, Vienna, Austria
[28] European AIDS Treatment Grp EATG, Brussels, Belgium
关键词
HIV; cohort; observational study; hepatitis; public health; tuberculosis; pharmacovigilance; ANTIRETROVIRAL THERAPY; RISK;
D O I
10.3390/microorganisms8081164
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases. Methods: RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12. Results: Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40-56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-naive, the median duration on ART was 10.1 years (4.8-17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/mu L (438-830). Malignancies (n= 361) and cardiovascular disease (n= 168) were the predominant reported clinical events. Conclusion: RESPOND's large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.
引用
收藏
页码:1 / 17
页数:16
相关论文
共 33 条
[1]   HIV and ageing: improving quantity and quality of life [J].
Althoff, Keri N. ;
Smit, Mikaela ;
Reiss, Peter ;
Justice, Amy C. .
CURRENT OPINION IN HIV AND AIDS, 2016, 11 (05) :527-536
[2]  
[Anonymous], **NON-TRADITIONAL**
[3]  
[Anonymous], 90 90 90 AMB TREATM
[4]  
[Anonymous], **NON-TRADITIONAL**
[5]  
[Anonymous], **NON-TRADITIONAL**
[6]  
[Anonymous], **NON-TRADITIONAL**
[7]  
[Anonymous], **NON-TRADITIONAL**
[8]  
[Anonymous], **NON-TRADITIONAL**
[9]  
[Anonymous], **NON-TRADITIONAL**
[10]  
[Anonymous], ETH PRINC MED RES IN